Hyperfine Management
Management Kriterienprüfungen 3/4
Hyperfine CEO ist Maria Degois-Sainz , ernannt in Oct 2022, hat eine Amtszeit von 3.58 Jahren. Die jährliche Gesamtvergütung beträgt $896.82K , bestehend aus 64.9% Gehalt und 35.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.04% der Aktien des Unternehmens, im Wert von $61.36K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.5 Jahre bzw. 4.4 Jahre.
Wichtige Informationen
Maria Degois-Sainz
Geschäftsführender
US$896.8k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 64.92% |
| Amtszeit als Geschäftsführer | 3.6yrs |
| Eigentum des Geschäftsführers | 0.04% |
| Durchschnittliche Amtszeit des Managements | 1.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.4yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • May 15
Hyperfine, Inc. (NASDAQ:HYPR) Analysts Are Pretty Bullish On The Stock After Recent Results
Hyperfine, Inc. ( NASDAQ:HYPR ) just released its quarterly report and things are looking bullish. Revenues were better...
Narrativ-Update • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Narrativ-Update • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Narrativ-Update • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Narrativ-Update • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Narrativ-Update • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Narrativ-Update • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Narrativ-Update • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Narrativ-Update • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Analyseartikel • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Narrativ-Update • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Narrativ-Update • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Narrativ-Update • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Narrativ-Update • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Narrativ-Update • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Narrativ-Update • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Analyseartikel • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Narrativ-Update • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Narrativ-Update • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Analyseartikel • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Analyseartikel • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Neues Narrativ • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Analyseartikel • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Analyseartikel • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Analyseartikel • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$35m |
| Dec 31 2025 | US$897k | US$582k | -US$36m |
| Sep 30 2025 | n/a | n/a | -US$40m |
| Jun 30 2025 | n/a | n/a | -US$39m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$2m | US$568k | -US$41m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$847k | US$550k | -US$44m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$4m | US$95k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$89m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$182k | n/a | -US$65m |
Vergütung im Vergleich zum Markt: MariaDie Gesamtvergütung ($USD896.82K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.71M).
Entschädigung vs. Einkommen: MariaDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Maria Degois-Sainz (59 yo)
3.6yrs
Amtszeit
US$896,817
Vergütung
Ms. Maria Degois-Sainz is Independent Director of Pulse Biosciences, Inc. from January 08, 2026. Ms. Degois-Sainz is Chair of the Board of Onera Technologies B.V. from January 2025. Ms. Degois-Sainz serves...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 3.6yrs | US$896.82k | 0.040% $ 61.4k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 25.3m | |
| Chief Administrative Officer | 3.3yrs | US$799.63k | 0.052% $ 78.8k | |
| Chief Operating Officer | 2.8yrs | US$799.63k | 0.13% $ 201.0k | |
| Vice President of Technology | 1.2yrs | keine Daten | keine Daten | |
| Senior Vice President of Office Strategy and Partnerships | 1.3yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 1.6yrs | keine Daten | keine Daten | |
| Senior Vice President of Hospital Business | 1.3yrs | keine Daten | keine Daten | |
| Chief Regulatory & Quality Officer | less than a year | keine Daten | keine Daten |
1.5yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: HYPRDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$896.82k | 0.040% $ 61.4k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 25.3m | |
| Independent Director | 4.8yrs | US$129.29k | 0.021% $ 31.7k | |
| Independent Director | 4.4yrs | US$129.63k | 0.020% $ 30.4k | |
| Independent Chairperson | 4.4yrs | US$197.37k | 0.020% $ 30.4k | |
| Member of Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten |
4.4yrs
Durchschnittliche Betriebszugehörigkeit
68yo
Durchschnittliches Alter
Erfahrener Vorstand: HYPRDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/17 20:40 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Hyperfine, Inc. wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |